CRISM Therapeutics Corporation
AMMCF
$6.77
$6.573,309.57%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 18.80K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 18.80K | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -984.50K | -984.50K | 984.50K | 984.50K | 255.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -984.50K | -984.50K | 984.50K | 984.50K | 255.00K |
| Operating Income | 984.50K | 984.50K | -984.50K | -984.50K | -255.00K |
| Income Before Tax | 984.50K | 984.50K | -984.50K | -984.50K | -445.50K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 984.50K | 984.50K | -984.50K | -984.50K | -445.50K |
| Earnings from Discontinued Operations | -1.20M | -1.20M | -3.63M | -3.63M | -85.50K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -211.00K | -211.00K | -4.61M | -4.61M | -531.00K |
| EBIT | 984.50K | 984.50K | -984.50K | -984.50K | -255.00K |
| EBITDA | -- | -- | -- | -67.40K | -185.70K |
| EPS Basic | -0.02 | -0.02 | -0.53 | -0.53 | -0.06 |
| Normalized Basic EPS | 0.07 | 0.07 | -0.07 | -0.07 | -0.02 |
| EPS Diluted | -0.02 | -0.02 | -0.53 | -0.53 | -0.06 |
| Normalized Diluted EPS | 0.07 | 0.07 | -0.07 | -0.07 | -0.02 |
| Average Basic Shares Outstanding | 8.71M | 8.71M | 8.70M | 8.70M | 8.71M |
| Average Diluted Shares Outstanding | 8.71M | 8.71M | 8.70M | 8.70M | 8.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -510.43% | -510.43% | -317.54% | -317.54% | -- |
